Rhumbline Advisers Citius Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.58 - $1.03 $73,550 - $130,615	-126,811 Reduced 80.85%	30,042 $17,000
Q1 2024 May 09, 2024	BUY	$0.6 - $0.9 $4,038 - $6,057	6,730 Added 4.48%	156,853 $141,000
Q4 2023 Feb 08, 2024	SELL	$0.65 - $0.86 $890 - $1,178	-1,370 Reduced 0.9%	150,123 $114,000
Q3 2023 Nov 09, 2023	BUY	$0.65 - $1.25 $4,722 - $9,082	7,266 Added 5.04%	151,493 $103,000
Q2 2023 Aug 08, 2023	BUY	$1.08 - $1.65 $155,765 - $237,974	144,227 New	144,227 $173,000
Q2 2022 Aug 11, 2022	SELL	$0.88 - $1.87 $109,819 - $233,366	-124,795 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.38 - $1.89 $28,726 - $39,342	20,816 Added 20.02%	124,795 $223,000
Q4 2021 Feb 10, 2022	SELL	$1.51 - $2.2 $5,964 - $8,690	-3,950 Reduced 3.66%	103,979 $160,000
Q3 2021 Nov 12, 2021	BUY	$1.74 - $2.6 $6,798 - $10,158	3,907 Added 3.76%	107,929 $219,000
Q2 2021 Aug 05, 2021	BUY	$1.51 - $4.23 $157,073 - $440,013	104,022 New	104,022 $362,000

23.7M

83.1K

32.1K

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $378M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.